Latest From Baylor University
The early successes enjoyed by new autologous, cell-based cancer therapies, as well as new advances in gene therapy and regenerative medicine, have reignited interest at Big Pharma in these advanced treatments, said partnering executives at the recent Therapeutic Area Partnerships meeting in Boston.
Groundbreaking new mapping technologies could shift the future direction of the $2.5 billion AF ablation market, as evidenced by presentations at this year’s HRS and EUROPACE meetings; with some compelling clinical data now on the books, the electrophysiologists who perform AF ablation are taking notice, as are investors and strategics operating in this space. Emerging companies at the heart of this shift include Topera Medical, CardioInsight Technologies, and Acutus Medical.
The acting head of Roche pharma research and early development stepped into the job amid major personnel changes in the pharma organization and the consolidation and streamlining of pRED. He spoke with the “The Pink Sheet” about his group’s priorities and the inevitable short-term hit to research productivity.
The ability to create and maintain a data stream of information that flows from medical devices into electronic health records (EHRs) is starting to become an important priority for some of the nation’s hospitals. The development is a natural outgrowth of the movement toward having a viable EHR for every patient, as well as the understanding that quality of care can be enhanced if those EHRs are fed the type of data that comes from devices such as ventilators, infusion pumps, anesthesia machines, and products that measure patient vital signs. That need is creating a new, niche market for companies that offer connectivity solutions, and at some point, these changes are predicted to alter the way hospitals choose which medical devices to purchase.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.